Results 261 to 270 of about 917,897 (332)

Daily dietary phosphorus intake variability and hemodialysis patient adherence to phosphate binder therapy

Hemodialysis international. International Symposium on Home Hemodialysis, 2019
Introduction: Phosphate balance could be reached only by an optimized combination of dietary restriction and the careful use of phosphate binders for patients receiving standard hemodialysis treatment.
Xingjuan Tao, Haifen Zhang, Yan Yang, Caihong Zhang, Min Wang   +4 more
semanticscholar   +1 more source

Hyperphosphatemia and phosphate binders

American Journal of Health-System Pharmacy, 2005
The pathophysiology of hyperphosphatemia associated with end-stage renal disease and treatment with phosphate binders are discussed.Phosphorus is an essential element necessary for the normal function of the human body, required for skeletal construction and synthesis of DNA, proteins, and adenosine triphosphate.
Jason J, Schucker, Kristina E, Ward
openaire   +2 more sources

The Phosphate Binder Ferric Citrate Alters the Gut Microbiome in Rats with Chronic Kidney Disease

Journal of Pharmacology and Experimental Therapeutics, 2018
In chronic kidney disease (CKD), the gut microbiome is altered and bacterial-derived uremic toxins promote systemic inflammation and cardiovascular disease.
W. Lau, N. Vaziri, A. Nunes, A. Comeau, M. Langille, W. England, M. Khazaeli, Yasunori Suematsu, J. Phan, Katrine L. Whiteson   +9 more
semanticscholar   +1 more source

The safety of phosphate binders

Expert Opinion on Drug Safety, 2006
Disturbances of mineral metabolism occur during the early stages of chronic kidney disease. As renal function worsens, excess dietary phosphorus accumulates and blood levels increase, that can be clearly seen when the glomerular filtration rate has fallen below 30 ml/min/1.73 m2.
Jaume, Almirall, Jaume Almirall, Daly, Maria Pau, Valenzuela, Maria Pau Valenzuela, Mujica   +3 more
openaire   +2 more sources

Lanthanum: A Safe Phosphate Binder

Seminars in Dialysis, 2006
ABSTRACTAccumulation of inorganic phosphate due to renal functional impairment contributes to the increased cardiovascular mortality observed in dialysis patients. Phosphate plays a causative role in the development of vascular calcification in renal failure; treatment with calcium‐based phosphate binders and vitamin D can further increase the Ca × PO4
Veerle P, Persy, Geert J, Behets, An R, Bervoets, Marc E, De Broe, Patrick C, D'Haese   +4 more
openaire   +2 more sources

The Phosphate Binder Equivalent Dose

Seminars in Dialysis, 2011
AbstractPhosphate binders include calcium acetate or carbonate, sevelamer hydrochloride or carbonate, magnesium and lanthanum carbonate, and aluminum carbonate or hydroxide. Their relative phosphate‐binding capacity has been assessed in human, in vivo studies that have measured phosphate recovery from stool and/or changes in urinary phosphate excretion
John T, Daugirdas, William F, Finn, Michael, Emmett, Glenn M, Chertow   +3 more
openaire   +2 more sources

Phosphate binders: New products and challenges

Hemodialysis International, 2006
AbstractOptimal phosphate control in dialysis patients is extremely challenging. A growing awareness of the deleterious effect of mineral metabolism imbalances together with the lack of a satisfactory explanation for the exaggerated mortality rate in patients undergoing renal replacement therapy has led to a renewed effort to refine our approach to ...
A. Bellasi, L. Kooienga, G. A. Block
openaire   +2 more sources

Next-Generation Phosphate Binders: Focus on Iron-Based Binders

Drugs, 2014
Phosphate excess is associated with increased mortality in patients with chronic kidney disease (CKD) and has recently been linked to accelerated aging. Oral phosphate binders are prescribed to patients with CKD to prevent absorption of dietary phosphate. Currently available binders have been associated with impaired outcomes (calcium-based binders) or
Dimitra, Nastou, Beatriz, Fernández-Fernández, Usama, Elewa, Liliana, González-Espinoza, Emilio, González-Parra, Maria D, Sanchez-Niño, Alberto, Ortiz   +6 more
openaire   +2 more sources

Reasons for Phosphate Binder Discontinuation Vary by Binder Type

Journal of Renal Nutrition, 2014
Nonadherence to phosphate binder regimen is common among end-stage renal disease patients and contributes to elevated phosphorus levels. Pill burden, side effects, complex regimens, and cost all contribute to nonadherence. We retrospectively analyzed reasons for discontinuation in hemodialysis patients receiving treatment at a large U.S.
Steven, Wang, Emmanuel A, Anum, Karthik, Ramakrishnan, Thomas, Alfieri, Peter, Braunhofer, Britt, Newsome   +5 more
openaire   +2 more sources

Lanthanum carbonate: a new phosphate binder

Current Opinion in Nephrology & Hypertension, 2004
Hyperphosphatemia remains an important aspect in the management of end-stage renal disease patients. Consequently, there is a need for new, efficient and well-tolerated phosphate binders. In this review, a new phosphate-binding drug, lanthanum carbonate, with an attractive preclinical efficacy profile compared with existing binders, is discussed ...
Behets, Geert, Verberckmoes, Steven, d' Haese, Patrick C., de Broe, Marc E.   +3 more
openaire   +3 more sources